Also known as: moderate-to-severe AD
Apogee Therapeutics will present Phase 2 APEX Part B data for zumilokibart on May 27, 2026. Affinity Asset Advisors increased its stake to 1.23 million shares valued at $93.21 million. The stock rose 86.9% over the past year.
Aclaris Therapeutics outlined its TSLP antibody and ITK kinase pipeline at the Guggenheim Biotech Summit, with Phase II AD results for bosakitug due in late 2026 and Phase 1b studies for bispecific ATI-052 underway. The company will also announce Phase 1a results for ATI-052 and lead indication selection for ATI-2138 on April 28, 2026.
Kyowa Kirin and Kura Oncology started a Japanese Phase II registrational study of ziftomenib in adults with relapsed or refractory NPM1-mutated AML. Kyowa Kirin plans to seek regulatory approval in Japan after the trial.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.
Phase 3 trial results show amlitelimab met primary endpoints in two monotherapy studies for moderate-to-severe atopic dermatitis, with combination therapy demonstrating the strongest efficacy. The investigational OX40L-targeting antibody showed comparable efficacy between every-4-week and every-12-week dosing intervals. Safety data revealed two cases of Kaposi sarcoma in patients with known risk factors among 4,630 exposed patients.
Two phase 3 trials demonstrate significant improvements in skin clearance and disease severity for children and adolescents with moderate-to-severe atopic dermatitis treated with targeted biologics.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07711418 |
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis |
RECRUITING | PHASE3 |
| NCT07690371 |
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis |
RECRUITING | PHASE3 |
| NCT07660835 |
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis |
RECRUITING | PHASE2 |
| NCT07502222 |
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07344051 |
A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07321951 |
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07211542 |
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis |
RECRUITING | PHASE2 |
| NCT06934252 |
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis |
RECRUITING | PHASE1 |
| NCT06158490 |
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT05984784 |
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) |
TERMINATED | PHASE1/PHASE2 |
